Perioperative Interdisciplinary, Intersectoral Process Optimization in Heart Failure
- Disease/Condition
- Heart Failure
- Drug/Device/Intervention
- Interdisciplinary decision-making for perioperative care
- Study type
- Interventional
- Intervention type
- other
- Primary sponsor
- University of Giessen
- Location
- Gießen, Germany
- Phase
- N/A
- Start date
- Sep 01, 2024
- End date
- Mar 01, 2027
- Enrollment
- 1057 participants
combined primary endpoint at 90 days post-operation : re-hospitalization,AKI, bacterial infection and cardiac decompensation
Chronic heart failure affects up to three million people in Germany, with prevalence
 increasing with age. It is a leading cause of cardiovascular disease-related deaths. Patients
 with heart failure undergoing non-cardiac surgery face higher risks of complications and
 death compared to those with coronary artery disease. Despite guidelines recommending
 comprehensive preoperative evaluation, there is no systematic risk assessment structure in
 place, leading to inadequate perioperative care. This study aims to evaluate a
 multidisciplinary approach for high-risk patients aged 65 and above, regardless of prior
 heart failure diagnosis, to mitigate postoperative complications. The investigators measure
 the NTpro BNP before surgery and include patients with NTproBNP 450 in this study and
 randomize them either to the standard care group or the intervention group.The hypothesis is
 that standardized risk screening and multidimensional care (Intervention group) can reduce
 complications in these patients undergoing non-cardiac surgery.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06381427
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06381427 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Giessen and is currently Not yet recruiting. The study focuses on Heart Failure. Target enrollment is 1057 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.